• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Pharmacokinetic and pharmacological features of oestradiol valerate.

作者信息

Düsterberg B, Nishino Y

出版信息

Maturitas. 1982 Dec;4(4):315-24. doi: 10.1016/0378-5122(82)90064-0.

DOI:10.1016/0378-5122(82)90064-0
PMID:7169965
Abstract

Natural oestrogenic hormones are the appropriate substances for the therapy of climacteric complaints. After oral or parenteral administration, oestradiol valerate, the synthesis compound contained in various commercially available preparations, is completely converted into the natural substances 17 beta-oestradiol and valeric acid. The 17 beta-oestradiol produced on cleavage of the ester behaves in the organism like the endogenous steroid hormone. Oestradiol valerate and 17 beta-oestradiol are virtually dose-equivalent. No differences in the spectrum of action of the oestrogen and its ester have been found either in animal experiments or man. The pharmacokinetic behaviour and the biotransformation of the 17 beta-oestradiol originating from oestradiol valerate are no different from those of natural 17 beta-oestradiol. Differences of practical significance exist in respect of the quantitative effect of oestradiol valerate following oral and intramuscular administration, whereas 4 mg oestradiol valerate administered intramuscularly is therapeutically sufficient for a period of 2-4 wk (depot effect). As much as 2 mg daily over 3 wk must be administered via the oral route to achieve the same effect. This difference is due to the greatly diverging pharmacokinetic behaviour of oestradiol valerate depending on which of the two modes of administration is employed.

摘要

相似文献

1
Pharmacokinetic and pharmacological features of oestradiol valerate.
Maturitas. 1982 Dec;4(4):315-24. doi: 10.1016/0378-5122(82)90064-0.
2
Pharmacokinetics and biotransformation of estradiol valerate in ovariectomized women.
Horm Res. 1985;21(3):145-54. doi: 10.1159/000180039.
3
A comparison of the pharmacokinetic properties of three estradiol esters.三种雌二醇酯的药代动力学特性比较。
Contraception. 1980 Apr;21(4):415-24. doi: 10.1016/s0010-7824(80)80018-7.
4
Endometrial and vaginal response to three different oestrogen preparations administered by the transdermal and oral routes.经皮和口服途径给予三种不同雌激素制剂后子宫内膜和阴道的反应。
Maturitas. 1988 Oct;10(3):181-92. doi: 10.1016/0378-5122(88)90021-7.
5
High fecundity rates in donor oocyte recipients and in-vitro fertilization surrogates using parenteral oestradiol valerate.使用戊酸雌二醇注射剂的供体卵母细胞受体和体外受精代孕者的高繁殖率。
Hum Reprod. 1993 Jul;8(7):1145-7. doi: 10.1093/oxfordjournals.humrep.a138209.
6
Changes in serum lipids during treatment with norgestrel, oestradiol-valerate and cycloprogynon.炔诺孕酮、戊酸雌二醇和炔雌醇环丙孕酮治疗期间血清脂质的变化。
Acta Obstet Gynecol Scand. 1977;56(4):367-70. doi: 10.3109/00016347709154994.
7
Pharmacokinetic interpretation of toxicity tests in rats treated with oestradiol valerate in the diet.饮食中戊酸雌二醇处理的大鼠毒性试验的药代动力学解释。
Pharmacol Toxicol. 1989 Sep;65(3):217-22. doi: 10.1111/j.1600-0773.1989.tb01160.x.
8
Bioavailability and pharmacodynamics of two 10-mg estradiol valerate depot formulations following IM single dose administration in healthy postmenopausal volunteers.两种10毫克戊酸雌二醇长效制剂在健康绝经后志愿者中单次肌内注射给药后的生物利用度和药效学
Int J Clin Pharmacol Ther. 2012 Feb;50(2):100-17. doi: 10.5414/cp201589.
9
Effect of oestriol, oestradiol valerate and ethinyloestradiol on serum proteins in oestrogen-deficient women.雌三醇、戊酸雌二醇和炔雌醇对雌激素缺乏女性血清蛋白的影响。
Maturitas. 1981 Dec;3(3-4):241-7. doi: 10.1016/0378-5122(81)90031-1.
10
Post natal oestrogen administration stimulates precocious endometrial gland development in the horse.产后雌激素给药可刺激马的子宫内膜腺过早发育。
Equine Vet J. 2009 Sep;41(7):678-84. doi: 10.2746/042516409x429428.

引用本文的文献

1
Thrombophilia and hormonal therapy in transgender persons: A literature review and case series.易性症患者的血栓形成倾向与激素治疗:文献综述及病例系列
Int J Transgend Health. 2022 Jan 20;23(4):377-391. doi: 10.1080/26895269.2022.2025551. eCollection 2022.
2
17β-Oestradiol Protects from Hepatitis C Virus Infection through Induction of Type I Interferon.17β-雌二醇通过诱导I型干扰素预防丙型肝炎病毒感染。
Viruses. 2022 Aug 18;14(8):1806. doi: 10.3390/v14081806.
3
A Comparative Study to Assess the Efficacy of Two Different Estradiol Formulations during In Vitro Fertilization.
一项评估两种不同雌二醇制剂在体外受精期间疗效的比较研究。
Int J Reprod Med. 2021 Aug 10;2021:3153307. doi: 10.1155/2021/3153307. eCollection 2021.
4
Evaluation of Uterine Artery Doppler and Estrogen Milieu in Oocyte Donation Pregnancies-A Pilot Study.卵母细胞捐赠妊娠中子宫动脉多普勒及雌激素环境的评估——一项初步研究
Diagnostics (Basel). 2020 Apr 26;10(5):254. doi: 10.3390/diagnostics10050254.
5
Vastly extended drug release from poly(pro-17β-estradiol) materials facilitates in vitro neurotrophism and neuroprotection.聚(原 17β-雌二醇)材料的药物释放大大延长,有助于体外神经营养和神经保护。
Nat Commun. 2019 Oct 23;10(1):4830. doi: 10.1038/s41467-019-12835-w.
6
Venous thrombosis and hormonal contraception: what's new with estradiol-based hormonal contraceptives?静脉血栓形成与激素避孕:基于雌二醇的激素避孕药有哪些新进展?
Open Access J Contracept. 2018 Nov 8;9:75-79. doi: 10.2147/OAJC.S179673. eCollection 2018.
7
Changes of The Uterine Tissue in Rats with Polycystic Ovary Syndrome Induced by Estradiol Valerate.戊酸雌二醇诱导的多囊卵巢综合征大鼠子宫组织的变化
Int J Fertil Steril. 2017 Apr-Jun;11(1):47-55. doi: 10.22074/ijfs.2016.4794. Epub 2016 Nov 11.
8
Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women.变性女性暴露前预防的药理学考量
J Acquir Immune Defic Syndr. 2016 Aug 15;72 Suppl 3(Suppl 3):S230-4. doi: 10.1097/QAI.0000000000001105.
9
Effect of the aqueous extract of Foeniculum vulgare (fennel) on the kidney in experimental PCOS female rats.小茴香水提取物对实验性多囊卵巢综合征雌性大鼠肾脏的影响。
Avicenna J Phytomed. 2014 Mar;4(2):110-7.
10
New and emerging contraceptives: a state-of-the-art review.新型及新兴避孕药具:最新综述
Int J Womens Health. 2014 Feb 19;6:221-34. doi: 10.2147/IJWH.S46811. eCollection 2014.